Zeitschrift für Komplementärmedizin 2017; 09(05): 28-33
DOI: 10.1055/s-0043-118915
Praxis
Umweltmedizin
© Karl F. Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Integrative Behandlung von Patienten mit Parkinson

Joachim Mutter

Subject Editor:
Further Information

Publication History

Publication Date:
19 September 2017 (online)

Zusammenfassung

In den meisten Fällen ist die Ursache einer Morbus-Parkinson-Erkrankung unklar. Die konventionellen Behandlungsoptionen sind nicht immer ausreichend oder werden aufgrund unerwünschter Wirkungen von den Patienten abgelehnt.

Verschiedene Studien legen den Einfluss von Umweltfaktoren auf die Entstehung neurodegenerativer Erkrankungen wie Morbus Parkinson nahe. Insbesondere Schwermetallbelastungen durch Zahnmaterialien scheinen eine Rolle zu spielen.

Mit einer integrativen Therapie, die u. a. die Ernährung, den Mikronährstoffstatus, Schwermetallbelastungen und mögliche neurotrope Infektionen berücksichtigt, kann der Behandlungserfolg erheblich verbessert bzw. die Krankheitsprogression gestoppt werden.

 
  • Literatur

  • 1 Berlin M, Zalups RK, Fowler BA. et al. In: Nordberg GF, Fowler BA, Nordberg M et al. eds Handbook on the Toxicology of Metals.. Vol. 2; 4th ed Amsterdam: Elsevier; 2015: 1013-1075
  • 2 Bjørklund G.. Parkinson’s disease and mercury.. J Orthomol Med 1995; 10 (02) 147-148
  • 3 Bjørklund G.. Parkinson disease, mercury and other heavy metals (in Norwegian).. Tidsskr Nor Laegeforen 1995; 115 (06) 757-222
  • 4 Bjørklund G. et al. Metals in Parkinson’s disease.. Current Medicinal Chemistry: 2017. (in press)
  • 5 Blázquez L, Otaegui DSáenz. et al. Apolipoprotein E epsilon4 allele in familial and sporadic Parkinson’s disease.. Neurosci Lett 2006; 406 (03) 235-239
  • 6 Egilman DS, Bohme SR.. Over a barrel: corporate corruption of science and its effects on workers and the environment. Int J Occup Environ Health 2005; 11 (04) 331-337
  • 7 Dantzig PI.. Parkinson’s disease, macular degeneration and cutaneous signs of mercury toxicity.. J Occup Environ Med 2006; 48 (07) 656
  • 8 David RA, Zimmermann MR.. Cancer: an old disease,. a new disease or something in between? Nature Reviews Cancer 2010; 10: 728-733
  • 9 de Lau LM, Breteler MM.. Epidemiology of Parkinson's disease.. Lancet Neurol 2006; 5 (06) 525-535
  • 10 Farrer LA, Cupples LA, Haines JL. et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease.. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997; 278 (16) 1349-1356
  • 11 Feng J, Auwaerter PG, Zhang Y.. Drug combinations against Borrelia burgdorferi persisters in vitro: eradication achieved by using daptomycin, cefoperazone and doxycycline.. PLoS One 2015; 10 (03) e0117207
  • 12 Feng J, Weitner M, Shi W. et al. Eradication of biofilm-like microcolony structures of Borrelia burgdorferi by daunomycin and daptomycin but not mitomycin C in combination with doxycycline and cefuroxime.. Front Microbiol 2016; 07: 62
  • 13 Feng J, Shi W, Zhang S. et al. A drug combination screen identifies drugs active against amoxicillin-induced round bodies of in vitro Borrelia burgdorferi persisters from an FDA drug library.. Front Microbiol 2016; 7-743
  • 14 Feng J, Zhang S, Shi W. et al. Ceftriaxone pulse dosing fails to eradicate biofilm-like microcolony B. burgdorferi persisters which are sterilized by daptomycin/doxycycline/cefuroxime without pulse dosing.. Front Microbiol 2016; 7-1744
  • 15 Godfrey ME, Wojcik DP, Krone CA. Apolipoprotein E genotyping as a potential biomarker for mercury neurotoxicity.. J Alzheimers Dis 2003; 5 (03) 189-195
  • 16 Goldman SM, Tanner CM, Olanow CW. et al. Occupation and parkinsonism in three movement disorders clinics.. Neurology 2005; 65 (09) 1430-1435
  • 17 Gratwicke J, Jahanshahi M, Foltynie T. Parkinson's disease dementia: a neural networks perspective.. Brain 2015; 138: 1454-1476 (Pt 6)
  • 18 Haley BE. Mercury toxicity: Genetic susceptibility and synergistic effects.. Med Veritas 2005; 535-542
  • 19 Hsu YC, Chang CW, Lee HL. et al. Association between history of dental amalgam fillings and risk of parkinson’s disease: A population-based retrospective cohort study in Taiwan.. PloS one 2016; 11 (12) e0166552.
  • 20 Lechner J, von Baehr V. RANTES and fibroblast growth factor 2 in jawbone cavitations:. triggers for systemic disease? Int J Gen Med 2013; 6: 277-290
  • 21 Leong CC, Syed NI, Lorscheider FL. Retrograde degeneration of neurite membrane structural integrity of nerve growth cones following in vitro exposure to mercury.. Neuroreport 2001; 12 (04) 733-737
  • 22 Lichtenstein P, Holm NV, Verkasalo PK. et al. Environmental and heritable factors in the causation of cancer – analyses of cohorts of twins from Sweden, Denmark, and Finland.. N Engl J Med 2000; 343: 78-85
  • 23 López M, Guerrero J, Yescas P. et al. Apolipoprotein E epsilon4 allele is associated with Parkinson disease risk in a Mexican Mestizo population.. Mov Disord 2007; 22 (03) 417-420
  • 24 Mangelsdorf I, Walach H, Mutter J.. Healing of Amyotrophic Lateral Sclerosis: a case report.. Complement Med Res 2017; 24 (03) 175-181
  • 25 Mutter J. Entgiftung: Effektiv bei vielen Krankheiten.. OM 2016; 4: 5-15
  • 26 Mutter J.. Lass Dich nicht vergiften. 5 Aufl.. GU: München; 2016
  • 27 Mutter J.. Is dental amalgam safe for humans? The opinion of the scientific committee of the European Commission.. J Occup Med Toxicol 2011; 6 (02) 1-17
  • 28 Mutter J. Gesund statt chronisch krank. 3. Aufl.. Weil der Stadt; Naturaviva: 2012
  • 29 Ngim CH, Devathasan G.. Epidemiologic study on the association between body burden mercury level and idiopathic Parkinson's disease.. Neuroepidemiology 1989; 8 (03) 128-141
  • 30 Olivieri G, Brack C. Müller-Spahn F et al. Mercury induces cell cytotoxicity and oxidative stress and increases beta-amyloid secretion and tau phosphorylation in SHSY5Y neuroblastoma cells.. J Neurochem 2000; 74 (01) 231-236
  • 31 Olivieri G, Novakovic M, Savaskan E. et al. The effects of beta-estradiol on SHSY5Y neuroblastoma cells during heavy metal induced oxidative stress, neurotoxicity and beta-amyloid secretion.. Neuroscience 2002; 113 (04) 849-855
  • 32 Papp A, Pecze L, Szabó A. et al. Effects on the central and peripheral nervous activity in rats elicited by acute administration of lead, mercury and manganese, and their combinations.. J Appl Toxicol 2006; 26 (04) 374-380
  • 33 Schubert J, Riley EJ, Tyler SA. Combined effects in toxicology – a rapid systematic testing procedure: cadmium, mercury, and lead.. J Toxicol Environ Health 1978; 4 (05) (06) 763-776
  • 34 Schulte PA, Burnett CA. Boeniger MF et al. Neurodegenerative diseases: occupational occurrence and potential risk factors, 1982 through 1991.. Am J Public Health 1996; 86 (09) 1281-1288
  • 35 Seidler A, Hellenbrand W, Robra BP. et al. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany.. Neurology 1996; 46 (05) 1275-1284
  • 36 Stewart WF, Schwartz BS, Simon D. et al. ApoE genotype, past adult lead exposure, and neurobehavioral function.. Environ Health Perspect 2002; 110 (05) 501-505
  • 37 Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer's disease.. Annu Rev Neurosci 1996; 19: 53-77
  • 38 Sun H. Association of soil selenium, strontium, and magnesium concentrations with Parkinson’s disease mortality rates in the USA.. Environ Geochem Health 2017; 7: 1-9
  • 39 Tanner CM, Kamel F, Ross GW. et al. Rotenone, paraquat, and Parkinson's disease.. Environ Health Perspect 2011; 119 (06) 866-872
  • 40 Tanner CM, Ottman R, Goldman SM. et al. Parkinson disease in twins: an etiologic study.. JAMA 1999; 281 (04) 341-346
  • 41 WHO – World Health Organization. Inorganic mercury. Environmental Health Criteria, 118. Geneva: World Health Organization 1991